Wuzhou Medical (301234):Will be listed on July 5, 2022 on the GEM Board of the Shenzhen Stock Exchange. The issuer is principally engaged in the research and development, production and sales of disposable sterile infusion medical devices, as well as the integrated supply of other related medical supplies for diagnosis and care. Its main products include syringes, infusion and transfusion devices, and medical puncture needles. The net profit attributable to owners of the parent company from 2019 to 2021 will be 52,899,600 yuan, 56,744,400 yuan and 68,392,300 yuan, respectively. It is reported that the proceeds, after deducting issuance costs, will be used for:Disposable infusion and puncture medical device technology expansion project, technology research and development center construction project, and supplementing working capital. *** Will raise funds of about 327 million yuan. Founded in 2011, the company has established a good reputation in the market of traditional infusion products by virtue of its highly automated production equipment, mature production technology, perfect product quality control system and rapid response service capability. Meanwhile, the Company is one of the earliest enterprises engaged in the development of safety infusion products in China, and some of its products now have mass production capacity. As of the signing date of the prospectus, the company has obtained 12 domestic medical device registration certificates. Among them, 10 certificates of registration for Class III medical devices and 2 certificates for Class II medical devices. 6 products have passed the CE certification of the European Union, and 14 products have been listed by the FDA of the United States. The sales of our products cover more than 80 countries and regions in Asia, Europe, South America, North America and Africa.
The company has established a wide range of continuous cooperative relationships with more than 300 customers.